Journal of Biological Chemistry · 2007 · 99 citations · 23 references
Life SciencesPharmacologyPharmacotherapyCell SignalingMolecular PharmacologySignal TransductionAdipose TissueAtherosclerosis PharmacotherapyG Protein-coupled Receptor SignalingLipid MetabolismLipid-lowering TherapyLipoprotein MetabolismAdipocyte BiologyAdipose Tissue LipolysisG Protein-coupled Receptor Control Of LipolysisHigh-density Lipoprotein MetabolismLipolytic Signaling PathwaysLow-density Lipoprotein Cholesterol LoweringNicotinic Receptor PharmacologyProstaglandin Signaling
Nicotinic acid remains the most effective therapeutic agent for the treatment and prevention of atherosclerosis resulting from low high density lipoprotein cholesterol. The therapeutic actions of nicotinic acid are mediated by GPR109A, a Gi protein-coupled receptor, expressed primarily on adipocytes, Langerhans cells, and macrophage. Unfortunately, a severe, cutaneous flushing side effect limits its use and patient compliance. The mechanism of high density lipoprotein elevation is not clearly established but assumed to be influenced by an inhibition of lipolysis in the adipose. The flushing side effect appears to be mediated by the release of prostaglandin D2 from Langerhans cells in the skin. We hypothesized that the signal transduction pathways mediating the anti-lipolytic and prostaglandin D2/flushing pathways are distinct and that agonists may be identified that are capable of selectively eliciting the therapeutic, anti-lipolytic pathway while avoiding the activation of the parallel flush-inducing pathway. We have identified a number of GPR109A pyrazole agonists that are capable of fully inhibiting lipolysis in vitro and in vivo and not only fail to elicit a flushing response but can antagonize the ability of nicotinic acid to elicit a flush response in vivo. In contrast to flushing agonists, exposure of cells expressing GPR109A to the non-flushing agonists fails to induce internalization of the receptor or to activate ERK 1/2 mitogen-activated protein kinase phosphorylation. Nicotinic acid remains the most effective therapeutic agent for the treatment and prevention of atherosclerosis resulting from low high density lipoprotein cholesterol. The therapeutic actions of nicotinic acid are mediated by GPR109A, a Gi protein-coupled receptor, expressed primarily on adipocytes, Langerhans cells, and macrophage. Unfortunately, a severe, cutaneous flushing side effect limits its use and patient compliance. The mechanism of high density lipoprotein elevation is not clearly established but assumed to be influenced by an inhibition of lipolysis in the adipose. The flushing side effect appears to be mediated by the release of prostaglandin D2 from Langerhans cells in the skin. We hypothesized that the signal transduction pathways mediating the anti-lipolytic and prostaglandin D2/flushing pathways are distinct and that agonists may be identified that are capable of selectively eliciting the therapeutic, anti-lipolytic pathway while avoiding the activation of the parallel flush-inducing pathway. We have identified a number of GPR109A pyrazole agonists that are capable of fully inhibiting lipolysis in vitro and in vivo and not only fail to elicit a flushing response but can antagonize the ability of nicotinic acid to elicit a flush response in vivo. In contrast to flushing agonists, exposure of cells expressing GPR109A to the non-flushing agonists fails to induce internalization of the receptor or to activate ERK 1/2 mitogen-activated protein kinase phosphorylation. Nicotinic acid (niacin, vitamin B3, pyridine-3-carboxylic acid) is the most effective therapeutic agent to date for raising high density lipoprotein (HDL) 2The abbreviations used are: HDL, high density lipoprotein; MAP, mitogen-activated protein; NEFA, non-esterified fatty acid; PGD2, prostaglandin D2; VLDL, very low density lipoprotein; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; HA, hemagglutinin; CHO, Chinese hamster ovary; PBS, phosphate-buffered saline; ERK, extracellular signal-regulated kinase. levels. It also offers protection against other cardiovascular risk factors by lowering very low density lipoprotein (VLDL), low density lipoprotein (LDL), and lipoprotein(a) plasma concentrations (1Carlson L.A. J. Intern. Med. 2005; 258: 94-114Crossref PubMed Scopus (504) Google Scholar, 2Offermanns S. Trends Pharmacol. Sci. 2006; 27: 384-390Abstract Full Text Full Text PDF PubMed Scopus (156) Google Scholar). Although the mechanism by which nicotinic acid raises HDL is not clear, one hypothesis is that it is the ability of nicotinic acid to inhibit lipolysis in adipocytes that results in a decrease in the concentration of free fatty acids available for the liver to use for triglyceride synthesis and VLDL production. The attenuated synthesis of the triglyceride-rich VLDL particles in the liver leads to a decreased rate of HDL metabolism via limiting the cholesterol ester transfer protein (CETP)-mediated exchange of cholesterol from HDL to VLDL, and triglyceride from VLDL to HDL (3Carlson L.A. Oro L. Acta Med. Scand. 1962; 172: 641-645Crossref PubMed Scopus (213) Google Scholar, 4Carlson L.A. Acta Med. Scand. 1963; 173: 719-722Crossref PubMed Scopus (134) Google Scholar, 5Carlson L.A. Ann. N. Y. Acad. Sci. 1965; 131: 119-142Crossref PubMed Scopus (43) Google Scholar, 6Carlson L.A. Orö L. J. Atheroscler. Res. 1965; 20: 436-439Abstract Full Text PDF Scopus (13) Google Scholar). Another hypothesis is that nicotinic acid inhibits the uptake and subsequent catabolism of Apo-AI-containing HDL particles in hepatocytes (7Jin F.Y. Kamanna V.S. Kashyap M.L. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 2020-2028Crossref PubMed Scopus (177) Google Scholar, 8Sakai T. Kamanna V.S. Kashyap M.L. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 1783-1789Crossref PubMed Scopus (107) Google Scholar). Identification of a high affinity nicotinic acid binding site that was localized to adipose, macrophage, and spleen tissues and appeared to function in a Gi protein-coupled manner (9Lorenzen A. Stannek C. Lang H. Andrianov V. Kalvinsh I. Schwabe U. Mol. Pharmacol. 2001; 59: 349-357Crossref PubMed Scopus (115) Google Scholar) led to the molecular identification of the high affinity nicotinic acid receptor GPR109A (HM74A in humans and PUMA-G in mice) (10Wise A. Foord S.M. Fraser N.J. Barnes A.A. Elshourbagy N. Eilert M. Ignar D.M. Murdock P.R. Steplewski K. Green A. Brown A.J. Dowell S.J. Szekeres P.G. Hassall D.G. Marshall F.H. Wilson S. Pike N.B. J. Biol. Chem. 2003; 278: 9869-9874Abstract Full Text Full Text PDF PubMed Scopus (461) Google Scholar, 11Tunaru S. Kero J. Schaub A. Wufka C. Blaukat A. Pfeffer K. Offermanns S. Nat. Med. 2003; 9: 352-355Crossref PubMed Scopus (658) Google Scholar, 12Soga T. Kamohara M. Takasaki J. Matsumoto S. Saito T. Ohishi T. Hiyama H. Matsuo A. Matsushime H. Furuichi K. Biochem. Biophys. Res. Commun. 2003; 303: 364-369Crossref PubMed Scopus (285) Google Scholar). In the adipose, GPR109A mediates an anti-lipolytic response that can attenuate cAMP-stimulated lipolysis (11Tunaru S. Kero J. Schaub A. Wufka C. Blaukat A. Pfeffer K. Offermanns S. Nat. Med. 2003; 9: 352-355Crossref PubMed Scopus (658) Google Scholar). A low affinity nicotinic acid receptor has also been identified, referred to as GPR109B or HM74 (11Tunaru S. Kero J. Schaub A. Wufka C. Blaukat A. Pfeffer K. Offermanns S. Nat. Med. 2003; 9: 352-355Crossref PubMed Scopus (658) Google Scholar). GPR109B appears to be the product of the gene duplication of GPR109A and is >95% identical to GPR109A. A search of available genomes indicates that this receptor is found only in the human and chimpanzee genomes and is absent in rodents. It is therefore difficult to know whether GPR109B has an endogenous ligand or plays a physiological role. The therapeutic value of nicotinic acid is limited by its major side effect, cutaneous flushing. This burning sensation, felt on the face and upper body, is responsible for a large portion of patient non-compliance (13Coronary Drug Project J. Am. Med. Assoc. 1975; 231: 360-381Crossref PubMed Scopus (1509) Google Scholar, 14Hiatt J.G. Shamsie S.G. Schectman G. Am. J. Manag. Care. 1999; 5: 437-444PubMed Google Scholar, 15McKenney J.M. Proctor J.D. Harris S. Chinchili V.M. J. Am. Med. Assoc. 1994; 271: 672-677Crossref PubMed Scopus (291) Google Scholar). Recent work has begun to elucidate the mechanism by which nicotinic acid induces flushing (16Benyó Z. Gille A. Kero J. Csiky M. Suchánková M.C. Nüsing R. Moers A. Pfeffer K. Offermanns S. J. Clin. Investig. 2005; 115: 3634-3640Crossref PubMed Scopus (288) Google Scholar, 17Benyó Z. Gille A. Bennett C.L. Clausen B.E. Offermanns S. Mol. Pharmacol. 2006; 70: 1844-1849Crossref PubMed Scopus (194) Google Scholar, 18Cheng K. Wu T.J. Wu K.K. Sturino C. Metters K. Gottesdiener K. Wright S.D. Wang Z. O'Neill G. Lai E. Waters M.G. Proc. Natl. Acad. Sci. U. S. A. 2006; 103: 6682-6687Crossref PubMed Scopus (264) Google Scholar, 19Maciejewski-Lenoir D. Richman J.G. Hakak Y. Gaidarov I. Behan D.P. Connolly D.T. J. Investig. Dermatol. 2006; 126: 2637-2646Abstract Full Text Full Text PDF PubMed Scopus (156) Google Scholar). GPR109A has been shown to mediate nicotinic acid-induced flushing through release of prostaglandin D2 (PGD2) and involves the activation of the DP1 receptor and possibly a PGE2 receptor (EP2 or EP4) (16Benyó Z. Gille A. Kero J. Csiky M. Suchánková M.C. Nüsing R. Moers A. Pfeffer K. Offermanns S. J. Clin. Investig. 2005; 115: 3634-3640Crossref PubMed Scopus (288) Google Scholar, 18Cheng K. Wu T.J. Wu K.K. Sturino C. Metters K. Gottesdiener K. Wright S.D. Wang Z. O'Neill G. Lai E. Waters M.G. Proc. Natl. Acad. Sci. U. S. A. 2006; 103: 6682-6687Crossref PubMed Scopus (264) Google Scholar) Recent work has further supported the hypothesis that it is GPR109A receptors on Langerhans cells in the skin that mediate nicotinic acid-induced flushing through generation of PGD2 (17Benyó Z. Gille A. Bennett C.L. Clausen B.E. Offermanns S. Mol. Pharmacol. 2006; 70: 1844-1849Crossref PubMed Scopus (194) Google Scholar, 19Maciejewski-Lenoir D. Richman J.G. Hakak Y. Gaidarov I. Behan D.P. Connolly D.T. J. Investig. Dermatol. 2006; 126: 2637-2646Abstract Full Text Full Text PDF PubMed Scopus (156) Google Scholar). A series of pyrazole derivatives have been reported in the literature that act as partial agonists for the nicotinic acid receptor (20van Herk T. Brussee J. van den Nieuwendijk A.M. van der Klein P.A. IJzerman A.P. Stannek C. Burmeister A. Lorenzen A. J. Med. Chem. 2003; 46: 3945-3951Crossref PubMed Scopus (105) Google Scholar). The authors postulate that tissue selectivity, commonly observed with partial agonists, could be useful in preventing unwanted effects on skin cells and thus reduce or eliminate flushing. In the work presented herein, we set out to test the hypothesis that there are GPR109A agonists that are effective anti-lipolytic agents that do not cause flushing. We find that we can divide GPR109A agonists into two groups, those that elicit an anti-lipolytic and a flushing response, exemplified by nicotinic acid, and those that only elicit an anti-lipolytic response, i.e. non-flushing agonists. This second group of non-flushing compounds significantly decreases plasma free fatty acids and not only fails to elicit a flushing response but can also block the flushing response of nicotinic acid. The non-flushing agonists are comprised of both full and partial agonists, depending on the functional output examined. We further characterized the signaling pathways elicited by these compounds and have shown that compounds that led to a flushing response also induce both ERK 1/2 mitogen-activated protein (MAP) kinase activation as well as receptor internalization. The non-flushing compounds fail to significantly activate ERK 1/2 MAP kinase and do not result in receptor internalization. These non-flushing agonists may have a therapeutic, anti-lipolytic benefit without the unwanted cutaneous flushing side effect. The GPR109A receptor was cloned and stable CHO-K1 cells were generated as described in Ref. 21Taggart A.K. Kero J. Gan X. Cai T.Q. Cheng K. Ippolito M. Ren N. Kaplan R. Wu K. Wu T.J. Jin L. Liaw C. Chen R. Richman J. Connolly D. Offermanns S. Wright S.D. Waters M.G. J. Biol. Chem. 2005; 280: 26649-26652Abstract Full Text Full Text PDF PubMed Scopus (439) Google Scholar. Animal studies were performed according to the Guide for the Care and Use of Laboratory Animals published by the National Academy of Sciences (1996). All study protocols were reviewed and approved by Arena Pharmaceutical's Internal Animal Care and Use Committee. C57Bl/6 mice were purchased from Jackson Laboratory, and jugular vein-catheterized Sprague-Dawley rats were purchased from Charles River Laboratories. A 96-well Adenylyl Cyclase Activation Flashplate Assay™ kit (PerkinElmer) was optimized to measure changes in intracellular cAMP levels due to receptor activation in CHO-K1 stable cell lines expressing GPR109A. CHO-K1 cells were cultured in F-12 Kaighn's modified cell culture medium with 10% fetal bovine serum, 2 mm l-glutamine, 1 mm sodium pyruvate, and 400 μg/ml Geneticin in T-185 cell culture flasks. Cells were harvested from culture flasks and via low and to a density of 1 were in and with phosphate-buffered Cells were to the test the compounds a cell density of was to The were on a for 1 with the was to well and the to for 2 The were on a of human adipocytes were from in 96-well 2 to the lipolysis medium was and of this medium was to Cells were in a and to for 1 of the of the lipolysis cells were with of the second and of of test compounds were to in were in 1 Cells were for was a free from medium was and to a 96-well A was to was on a The of was on of concentrations a were to the were with or the of the concentration in the were via and was by The was on a for was in a for and to a 96-well for The was according to the of for of for and for was on a of Sprague-Dawley rats were with of and were for All were by a flush to of the were via and rats were or or via was to a and on The was on a for was in a and as described for the mice were with via the was an and a and or or was in the and a was to of The of the was to the side The was in the of the and as medium very and from a or was into the through the and for a was with the that the the was with or This was by and nicotinic acid) as described In this of flushing was by and PGD2 as a MAP kinase were performed the kinase kit from according to the CHO-K1 stable cell lines expressing GPR109A were Cells were with compounds for the medium was and the cells were with The cells were in 1 of and to a The was for and the was in of cell The were on for and by for concentrations were by a modified and of protein was to well of a 96-well with kinase The were for 2 and with the kinase for 1 The were and with an for The were and with in the for the with was on a the MAP kinase mice were with or mice were via and the were into and in a protein was via were in of cell and as described cells were with human or GPR109A and human and on in internalization was Cells were with and on for 1 with μg/ml in concentrations of compounds were to the cells and for of Cells were with and with were on for cells were and cultured as described in Ref. 19Maciejewski-Lenoir D. Richman J.G. Hakak Y. Gaidarov I. Behan D.P. Connolly D.T. J. Investig. Dermatol. 2006; 126: 2637-2646Abstract Full Text Full Text PDF PubMed Scopus (156) Google Scholar. The PGD2 of culture medium was as described in Ref. 19Maciejewski-Lenoir D. Richman J.G. Hakak Y. Gaidarov I. Behan D.P. Connolly D.T. J. Investig. Dermatol. 2006; 126: 2637-2646Abstract Full Text Full Text PDF PubMed Scopus (156) Google 2 the of cell was to 400 of or and for of 1 mm nicotinic acid, or were to well and the cells were further for and as described in Ref. 19Maciejewski-Lenoir D. Richman J.G. Hakak Y. Gaidarov I. Behan D.P. Connolly D.T. J. Investig. Dermatol. 2006; 126: 2637-2646Abstract Full Text Full Text PDF PubMed Scopus (156) Google Scholar. used in the described are shown in CHO-K1 cells were with GPR109A and cAMP was in the were the concentrations to measure ability to inhibit cAMP and nicotinic acid was used as the full and cAMP to the as nicotinic acid were full and were to inhibit only of the cAMP were partial These compounds the and to cAMP cells with or GPR109A. The partial agonists and were to acid binding and were to fully acid binding not of cAMP in CHO-K1 GPR109A agonists were the concentrations to measure ability to inhibit cAMP production. Nicotinic acid was used as the full inhibition of cAMP to nicotinic acid are shown in the the inhibition of cAMP to nicotinic We the ability of these compounds to inhibit human lipolysis in an in vitro adipocytes were cultured and as described was with 1 and compounds were to ability to inhibit the results of the lipolysis All of the compounds lipolysis with All but one appeared to inhibit lipolysis to the as nicotinic acid full was only to decrease to of the value that it is a partial in this We the effect of these GPR109A agonists on plasma free fatty acid concentrations in vivo in C57Bl/6 of the compounds were to plasma free fatty acid concentrations to an or nicotinic acid This effect appeared to be for of the agonists examined. The of the compounds but not the in of the agonists. This the we the GPR109A agonists to an in vivo of plasma free fatty acid we found All of the compounds and plasma free fatty acids levels The of plasma free fatty acid inhibition was for of the agonists to inhibition of The cutaneous flushing by these agonists was via and thus on the of C57Bl/6 that of the GPR109A agonists described led to a flushing response acid, and not and a non-flushing GPR109A was into the mice to to nicotinic acid nicotinic acid was to elicit a flushing response were performed with a PGD2 the with a full flushing response not These that the non-flushing is to with receptors on the cells responsible for mediating the flushing response and the nicotinic flushing effect of nicotinic acid-induced flush in C57Bl/6 mice were of or to with the was established by of nicotinic acid. are the from acid of or as in the of the ability of nicotinic acid to induce a flushing ERK 1/2 MAP kinase were performed on the GPR109A of the compounds only the flush-inducing compounds nicotinic acid, and MAP kinase activation the other the compounds and to significantly ERK 1/2 MAP kinase It was that and receptor internalization are for MAP kinase activation by Y. S. M.G. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus (461) Google Scholar). test we the ability of these compounds to GPR109A in the effects of nicotinic acid and on the of GPR109A. of exposure of the cells to and nicotinic acid or the appears to in a the and of receptor internalization. the other a non-flushing to effect in the hypothesis that this fails to receptor internalization to other GPR109A agonists described herein, the of GPR109A nicotinic acid results in receptor non-flushing compounds and fail to receptor of GPR109A internalization exposure for of GPR109A was on cells of exposure to of shown are of Recent work the mechanism of flushing has that it is mediated by GPR109A (16Benyó Z. Gille A. Kero J. Csiky M. Suchánková M.C. Nüsing R. Moers A. Pfeffer K. Offermanns S. J. Clin. Investig. 2005; 115: 3634-3640Crossref PubMed Scopus (288) Google Scholar) and the release of PGD2 and activation of DP1 receptors in the skin K. Wu T.J. Wu K.K. Sturino C. Metters K. Gottesdiener K. Wright S.D. Wang Z. O'Neill G. Lai E. Waters M.G. Proc. Natl. Acad. Sci. U. S. A. 2006; 103: 6682-6687Crossref PubMed Scopus (264) Google Scholar) that the PGD2 release is mediated by Langerhans cells (17Benyó Z. Gille A. Bennett C.L. Clausen B.E. Offermanns S. Mol. Pharmacol. 2006; 70: 1844-1849Crossref PubMed Scopus (194) Google Scholar, 19Maciejewski-Lenoir D. Richman J.G. Hakak Y. Gaidarov I. Behan D.P. Connolly D.T. J. Investig. Dermatol. 2006; 126: 2637-2646Abstract Full Text Full Text PDF PubMed Scopus (156) Google Scholar). on the results shown we that GPR109A agonists activate a MAP release of PGD2 from Langerhans cells, to the cutaneous responsible for the flushing shown in mice an a elevation of kinase in the flushing is in the cells were and treatment led to a release that was attenuated by with the This effect was also in cultured human Langerhans cells both the and were to attenuate PGD2 release Although in vivo use of the to flushing was by its to inhibit MAP kinase in this the results are with a MAP kinase for flushing. The results presented that there are GPR109A agonists nicotinic acid, are capable of the inhibition of inhibit lipolysis in adipocytes, and decrease plasma free fatty acids in both mice and rats but that the ability to induce receptor internalization and ERK 1/2 MAP kinase We find that the compounds that into this group fail to elicit a flushing response in can antagonize the flushing response elicited by nicotinic acid. These results that it may be to anti-lipolytic compounds that fail to induce the unwanted flushing side effect in nicotinic acid The that a receptor may selectively activate only a of signal distinct from other agonists via a receptor has been for a number of protein-coupled This may result the are and the agonists used have resulting in signal may induce a to a to activate a is capable of eliciting a signal that is not to activate the second pathway. it has been that receptors as protein-coupled receptors have one In this one induce a capable of parallel induces a receptor only capable of eliciting a of signaling This of signaling has been of receptor T. Trends Pharmacol. Sci. Full Text PDF PubMed Scopus Google Scholar). The that agonists may induce receptor or may have signal and therefore signaling has been by a number of for a of protein-coupled receptors the receptor, and the nicotinic acid receptor Herk T. Brussee J. van den Nieuwendijk A.M. van der Klein P.A. IJzerman A.P. Stannek C. Burmeister A. Lorenzen A. J. Med. Chem. 2003; 46: 3945-3951Crossref PubMed Scopus (105) Google Scholar, Wilson Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google Scholar, H. E. 1999; 21: Scholar, S. J. C. Mol. Pharmacol. PubMed Scopus Google Scholar, H. N. IJzerman A.P. J. Med. Chem. PubMed Scopus Google Scholar, IJzerman A.P. M. J. Pharmacol. PubMed Scopus Google and reviewed by T. Ref. T. Trends Pharmacol. Sci. Full Text PDF PubMed Scopus Google Scholar). In these studies it is that use of one or may elicit and distinct from elicited by or These have been by a number of for the use of partial agonists, compounds that receptors but in which activation not to a fully response, to elicit a response without an side effect. it was shown by Wilson Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google Scholar) that use of an receptor partial has an effect in C57Bl/6 mice while avoiding the side effect elicited by the full In this study it is to that agonists elicit in vitro with of as a function of the MAP kinase In the receptor density and are to in tissues and therefore the of agonists also The authors that partial agonists can pathways and may be used to Wilson Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google Scholar). described in the a series of pyrazole derivatives have been reported in the literature that act as partial agonists for binding via the nicotinic acid receptor in and spleen (20van Herk T. Brussee J. van den Nieuwendijk A.M. van der Klein P.A. IJzerman A.P. Stannek C. Burmeister A. Lorenzen A. J. Med. Chem. 2003; 46: 3945-3951Crossref PubMed Scopus (105) Google Scholar). The authors postulate that tissue selectivity, commonly observed with partial agonists, could be useful in preventing flush-inducing side effects on skin cells while the ability to inhibit In of the compounds presented herein, we effects inhibiting cAMP we identified full agonists and and two partial agonists and of are non-flushing compounds full and both of the partial These effects are of the of the receptor as the and of these compounds were identical in or In the in vitro lipolysis one of the is a partial this is a flush It be that these compounds have or affinity to the low affinity In as in the GPR109B not to have a effects mediated by the of presented be on the of the of in to a therapeutic effect without the unwanted side effect not the of partial agonists. the and identification be on identification of agonists that of to mediate therapeutic and that the ability to that mediate side the mechanism of therapeutic of nicotinic acid has to be identified, one be that the side effect may also eliminate the therapeutic effect. and studies to be the therapeutic of compounds that into the two those that elicit MAP kinase and internalization in to eliciting an anti-lipolytic response those that elicit an anti-lipolytic We Chen and N. for the generation of cell lines and
23
Clofibrate and Niacin in Coronary Heart Disease
JAMA · 1975 · 1.7K citations
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect
Sorin Tunaru, Jukka Kero, Annette Schaub et al. · Nature Medicine · 2003 · 795 citations
Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid
Alan Wise, Steven M. Foord, Neil J. Fraser et al. · Journal of Biological Chemistry · 2003 · 541 citations · Full text
Medicine, Biochemistry, Pharmacology +17